Xortx Therapeutics inc (XRTX) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access XRTX Annual Income Statement →
Income statement data covering Xortx Therapeutics inc–Dec 31 2024 offers a view into how Dec 31 2025's operating results have moved alongside business activity.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue0.60
Costs & Expenses
Gross Profit0.60
Selling, Administration, Marketing0.24
Research and Development Expense0.57
Other Operating Expense / -Income1.22
Total operating costs including COS2.03
Operating income / -loss-1.44
Net Interest Expense / -Income0.00
Other loss / -income1.68
Total costs & expenses3.85
Income & Taxes
Income / -loss before income taxes-3.26
Income after income taxes-3.26
Net income / -loss of other equity3.26
Income / -loss from continuing operations0.00
Net income / -loss0.00
Income / -loss to shareholder0.00
EBIT-3.26
EBITD-3.26
EBITDA-3.26
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)4.73
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)4.73
4 historic quarters locked

Sign in to unlock the full Xortx Therapeutics inc income statement history.

About XRTX Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.